Obesity Abstracts

Background: Obesity is an important predictor for development of obstructive sleep apnoea (OSA). Patients undergoing bariatric surgery are at increased risk of peri-operative morbidity from undiagnosed OSA. We aim to assess the prevalence and severity of OSA, and its association with the Epworth Screening Scale (ESS) in a bariatric surgical population.Methods: Retrospective study of adult patients who attended the Tier 4 Medical Obesity Clinic (MOC) at G...

Background: Ethnicity and obesity have been recently established as risk factors for adverse coronavirus disease 19 (COVID-19) outcomes. The prevalence of obesity differs across ethnic groups. Thus, previously reported ethnic differences in COVID-19 outcomes may be due to underlying variations in BMI.Aims: To investigate the association between ethnicity and in-hospital mortality in COVID-19, and the effect of BMI. The secondary aim was to investigate th...

Until recently, only two medications were licenced and approved by the National Institute of Health and Care Excellence (NICE) for weight loss, orlistat and liraglutide. Semaglutide 2.4mg was launched in September 2023. Both liraglutide and semaglutide belong to a class of drugs called GLP-1 analogues, also used in the treatment of Type 2 diabetes. Successful weight loss outcomes for GLP-1 analogues has led to increased global demand and shortages. In June 2023, a National Pat...